GENE ONLINE|News &
Opinion
Blog

2018-12-06| PartnerAsia-Pacific

2018 MEDTEX Summit: CEO Perspectives

by GeneOnline
Share To

By Joanne Shih

The 2018 Med x Tech Summit Asia (MEDTEX) opened on November 30 in Taipei, Taiwan. At the CEO Forum, leaders from pharmaceutical and IT companies, including Merck, Teva, Hitachi, NVIDIA, and Qisda talked about the future of healthcare industry and intersectional possibilities.

Progress and Challenge in Healthcare Transformation

Many of them emphasized collaboration and partnership are the key to build a thriving future. While collaboration is pivotal to healthcare transformation, interdisciplinary communication is even more important. Murakami Sei from Hitachi believed that applying artificial intelligence (AI) and Internet of Things (IoT) on traditional medicine will be the trend in the near future. However, the challenge is how to effectively communicate with professionals from diverse fields. Sei said, “Each field has its own “language”. You need to speak differently with IT professionals than with clinicians.”

Rohan O’Reilly, Co-founder of Neuromersiv, at MEDTEX Session III introduced the concept of neuroplasticity, and explained how virtual reality can greatly improve neural rehabilitation. (Photo Credit/GeneOnline)
Rohan O’Reilly, Co-founder of Neuromersiv, at MEDTEX Session III introduced the concept of neuroplasticity, and explained how virtual reality can greatly improve neural rehabilitation. (Photo Credit/GeneOnline/Joanne Shih)

How to Stay Innovative?

The moderator, Chairman of IBMI, Simon Chang tossed a question to the guests asking “How do you push yourself to stay innovative?” Sei first answered, “In Hitachi, we focus on advancing technology while striving to translate technology into practical tools. If you cannot bring technology into market, technology is pointless.” Birgit Reitmaier, Head of Access to Innovation APAC at Merck, said, “Diversity is the key to constantly stay innovative. Internally we keep an open eye, but externally keep scouting to outer world.” Larry Merizalda from Teva, an Israel-based company, had a different voice noting the importance of finding strength from within. Merizalda said, “We feed ourselves with the innovation coming from our own country, and leverage internal innovation to international level. Eunice Chiu, Vice President at NVIDA Taiwan, believed that innovation comes from integrating new technology into current system and healthcare startups have potential to make significant impact. She also encouraged researchers to connect with international talents and learn from one another. Harry Yang from Qisda suggested that organizations in Taiwan should work together in order to operate in an international scale and to achieve further goal.

CEO of Israel Advanced Technology Industries (IATI), Karin Mayer Rubinstein at MEDTEX looked for international partnership. (Photo Credit/GeneOnline/Joanne Shih)
CEO of Israel Advanced Technology Industries (IATI), Karin Mayer Rubinstein at MEDTEX looked for international partnership. (Photo Credit/GeneOnline/Joanne Shih)

Criteria for Ideal Partners

Sei representing Hitachi said that they are looking for partners with broad range of knowledge and collaborative mindset. Reitmaier at Merck expressed that they are open to partner with people from anywhere on the world while actively looking exploring partnership in Asia. Merizalda from Teva noted that Teva is a multinational company and has comprehensive system and complex administration. Thus, Merizalda encouraged business to be patient when working with company as such. Eunice Chiu from NVIDA, standing for AI computing company said that a compatible partner need to be equipped with three character: 1) being acceptive to technology; 2) having sufficient data; and 3) being willing to share data and to collaborate.

 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Synthetic Biology’s Innovator Dr. John Cumbers – Addressing Inefficiencies in Biopharma and Economic Sustainability
2024-07-11
$115M Series A Boosts Myricx Bio’s ADC Development with Lilly and Novo Support
2024-07-11
Merck Buys EyeBio for $3B and Shares Global Policy Perspectives During BIO in San Diego
2024-06-20
LATEST
Eli Lilly’s Tirzepatide Gets Approval in China for Weight Loss Management
2024-07-22
Roche Reports Positive Clinical Trial Results for Two Diabetes-Related Eye Disease Therapies
2024-07-19
7th Person in History Possibly Cured From HIV After Stem Cell Transplant for Acute Myeloid Leukemia
2024-07-19
Large RCT Finds Time-Lapse Imaging for Embryo Selection in IVF Does Not Improve Live Birth Rates
2024-07-19
Assessment of Supply Chain Risk Key to Improving Medicine Access
2024-07-18
SK Biopharma and Full-Life Sign US$571.5 Million Deal for Innovative Radiopharmaceutical FL-091
2024-07-18
Autoimmune Patients See Breakthrough Response to Allogeneic CD19-Targeted CAR-T Therapy
2024-07-18
EVENT
Scroll to Top